44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
May 2026 in “Indian Journal of Dermatology” Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
April 2022 in “Reactions Weekly”
4 citations
,
July 2021 in “Cancer Research and Treatment” Temozolomide improves survival in grade III glioma patients without harming quality of life.
26 citations
,
January 2016 in “Indian journal of endocrinology and metabolism” Both metformin and pioglitazone improve PCOS symptoms, but pioglitazone is a good alternative for those who can't take metformin.
37 citations
,
January 2006 in “Carcinogenesis” Antizyme slows skin tumor growth by reducing cell growth in mice.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
42 citations
,
August 1972 in “Archives of Disease in Childhood” Fetal exposure to diazoxide can cause hair loss and abnormal hair growth in infants.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
24 citations
,
May 1982 in “Biochemical Pharmacology” These drugs cause hair growth without affecting testosterone or adrenal hormones.
14 citations
,
July 2012 in “Journal of the American Academy of Dermatology” Topical tacalcitol ointment can help improve symptoms of EFFC.
10 citations
,
August 2022 in “JAAD Case Reports” Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
June 2024 in “European neuropsychopharmacology”
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
4 citations
,
February 2011 in “Nature Reviews Endocrinology” Metformin and thiazolidinediones are similarly effective for PCOS, but metformin is often preferred due to fewer side effects.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
80 citations
,
August 1991 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Methotrexate reduced the need for steroids in asthma patients without worsening their condition.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
2 citations
,
March 2025 in “ESMO Open” Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.